Lebwohl David
SEC insider (Form 3/4/5 filer). CIK 0001810882. EVP, Chief Medical Officer at Intellia Therapeutics, Inc. (NTLA). 5 reported Form 4/5 transactions since Sep 2024; latest on Mar 1, 2026. Located in CAMBRIDGE, MA.
Companies Lebwohl David has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Officer, EVP, Chief Medical Officer
Lebwohl David
CIK: 0001810882
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (40.0%)
Position reduction
Option Exercises (M)1 (20.0%)
Derivative conversions
Awards (A)2 (40.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
NTLA
Intellia Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (5 total)
- Mar 1, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect9.9K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect11.9K shares at avg. $9.21$110K - Mar 1, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect43.2K shares- - Jan 3, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect9.6K shares at avg. $12.18$116K - Jan 1, 2025NTLA
Intellia Therapeutics, Inc.
ExerciseDirect3.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 1, 2026 | NTLA Intellia Therapeutics, Inc. | Award | 9,943 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 11,903 | $9.21 | $109,627 | Direct |
| Mar 1, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 43,200 | - | - | Direct |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 9,557 | $12.18 | $116,404 | Direct |
| Jan 1, 2025 | NTLA Intellia Therapeutics, Inc. | Exercise | 3,189 | - | $0 | Direct |
1-5 of 5 transactions